01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported product revenues, net, of $93.4 milliona for the three months ended September 30, 2024, up from $79.1 million a year earlier, an increase of 18.2% driven by ARIKAYCE sales in the US, Japan and Europe and the rest of the world.
For the nine months, product revenues were $259.3 millionb, up 17.0% from $221.5 million. The company still reported a net loss of $220.5 million for the quarter ($1.27 per share) and $678.2 million for the nine months. Operating expenses rose, with R&D expense of $150.8 million for the quarter versus $109.1 million a year earlier, and SG&A expense of $118.9 million versus $90.6 million, which management attributed partly to commercial readiness activities for brensocatib.
The change in fair value of deferred and contingent consideration liabilities was $106.5 millionc for the nine months, which the filing says was primarily due to the increase in the company's share price. The balance sheet strengthened substantially during 2024. Cash and cash equivalents were $461.5 million and marketable securities were $1.0 billion at September 30, 2024, and working capital was $1,390.7 million.
Shareholders' equity moved to $483.4 milliond from a deficit of $(331.9) million at December 31, 2023. The increase was supported by a May 2024 common stock offering with net proceeds of $713.2 million and $371.3 million of net proceeds from the new at-the-market program in the third quarter. The company also redeemed its 2025 Convertible Notes on August 9, 2024, with holders converting $224.8 million of principal into 5,741,063 shares.
Management states it currently has sufficient funds for at least the next 12 months, while operating cash outflow was $487.9 million for the nine months. The key pipeline milestone is brensocatib in bronchiectasis. The company reported positive topline results from the Phase 3 ASPEN trial in May 2024, with both doses showing statistically significant reductions in the annualized rate of adjudicated pulmonary exacerbations versus placebo.
The company remains on track to file a New Drug Application with the FDA in the fourth quarter of 2024 and, if priority review is granted and the drug is approved, anticipates a US launch in mid-2025. The filing also notes that AstraZeneca's second and final option on brensocatib for COPD or asthma expired in June 2024 without an agreement, so Insmed retains full worldwide rights outside those indications.
02—Key points
Key Highlights
- Product revenues, net, rose 18.2% to $93.4 million in Q3 2024 from $79.1 million, and 17.0% to $259.3 million for the nine months, driven by ARIKAYCE growth in the US, Japan and Europe and the rest of the world.
- Net loss was $220.5 million for Q3 2024 ($1.27 per share) and $678.2 million for the nine months, compared with $158.9 million and $563.5 million in the prior-year periods.
- R&D expense rose to $150.8 million in Q3 2024 from $109.1 million, mainly from manufacturing and compensation-related costs; SG&A expense rose to $118.9 million from $90.6 million.
- Cash and cash equivalents of $461.5 million and marketable securities of $1.0 billion at September 30, 2024; working capital was $1,390.7 million.
- Equity financing raised $713.2 million net from a May 2024 offering and $371.3 million net from the new ATM program in Q3, with $120.1 million remaining available under the ATM program.
- Brensocatib's ASPEN Phase 3 trial met its primary endpoint in bronchiectasis; the NDA filing is planned for Q4 2024, with a US launch anticipated in mid-2025 if priority review is granted and the drug is approved.
- Contingent consideration liabilities increased to $183.7 million from $84.6 million at December 31, 2023, and the company redeemed its 2025 Convertible Notes in August 2024.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $93.42M$79.07M | +18.2% |
| Cost of Revenue | $21.17M$16.71M | +26.7% |
| Gross Profit | $72.25M$62.37M | +15.9% |
| R&D Expenses | $150.81M$109.15M | +38.2% |
| SG&A Expenses | $118.93M— | — |
| Operating Expenses | $306.85M$226.74M | +35.3% |
| Operating Income | -$213.43M-$147.67M | −44.5% |
| Interest Expense | $21.05M$20.29M | +3.8% |
| Net Income | -$220.52M-$158.93M | −38.8% |
| EPS (Basic) | $-1.27$-1.11 | −14.4% |
| EPS (Diluted) | $-1.27$-1.11 | −14.4% |
| Shares Outstanding (Basic) | 173.72M142.90M | +21.6% |
| Shares Outstanding (Diluted) | 173.72M142.90M | +21.6% |
05—Questions
Frequently Asked Questions
How did ARIKAYCE sales perform in the third quarter of 2024?
Product revenues, net, were $93.4 million for the three months ended September 30, 2024, up 18.2% from $79.1 million. US revenues were $66.9 million (up 12.9%), Japan revenues were $21.0 million (up 30.9%), and Europe and rest of world revenues were $5.6 million (up 45.3%).
Does Insmed have enough cash to fund operations?
The company states that it currently has sufficient funds to meet its financial needs for at least the next 12 months. At September 30, 2024, it held $461.5 million in cash and cash equivalents and $1.0 billion in marketable securities. It also notes that it may raise additional capital in the future and that its expected future cash requirements are substantial.
What are the next regulatory steps for brensocatib?
The company remains on track to file a New Drug Application with the FDA for brensocatib in patients with bronchiectasis in the fourth quarter of 2024. If priority review is granted and the drug is approved, Insmed anticipates a US launch in mid-2025. Launches in Europe and Japan are expected in the first half of 2026, pending approvals.
Why did the change in fair value of contingent consideration reach $106.5 million for the nine months?
The filing states that the change in fair value of deferred and contingent consideration for the nine months ended September 30, 2024 was primarily due to the increase in the company's share price. These liabilities relate to potential future consideration payable to former equityholders of businesses Insmed acquired, and their fair value was $183.7 million at September 30, 2024.
What happened to the 2025 Convertible Notes?
Insmed called the outstanding 2025 Convertible Notes for redemption with a redemption date of August 9, 2024. Holders of $224.8 million aggregate principal amount converted into 5,741,063 shares of common stock, and the remaining $0.2 million principal was redeemed at 100% of principal plus accrued interest. No 2025 Convertible Notes were outstanding at September 30, 2024.
06—Continue